NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Short Interest Update

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 121,686 shares, an increase of 5,453.9% from the December 31st total of 2,191 shares. Currently, 3.2% of the company’s stock are short sold. Based on an average daily volume of 329,044 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 329,044 shares, the days-to-cover ratio is presently 0.4 days. Currently, 3.2% of the company’s stock are short sold.

NLS Pharmaceutics Stock Down 5.0%

NLS Pharmaceutics stock opened at $2.64 on Thursday. The business’s fifty day moving average is $2.85 and its 200 day moving average is $12.56. NLS Pharmaceutics has a one year low of $1.89 and a one year high of $33.70.

Analysts Set New Price Targets

Several research firms recently weighed in on NCEL. Weiss Ratings restated a “sell (e+)” rating on shares of NLS Pharmaceutics in a research note on Tuesday, October 14th. Wall Street Zen downgraded NLS Pharmaceutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About NLS Pharmaceutics

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.